Literature DB >> 21880197

Higher serum potassium level associated with late stage chronic kidney disease.

Ming-Fang Hsieh1, I-Wen Wu, Chin-Chan Lee, Shun-Yin Wang, Mai-Szu Wu.   

Abstract

BACKGROUND: The serum potassium (K+) level is kept in a narrow range to sustain normal physiology within the human body by the kidneys. The serum K+ level in different stages of chronic kidney disease (CKD) remains undefined.
METHODS: We conducted a cross-sectional study to observe the serum K+ level in patients without clinical manifestations of hyperkalemia in the late stages of CKD (stages 3-5). A total of 531 patients with late stage CKD were included and followed up for at least 1 year, from March 2006 to May 2007. The patients were sub-grouped by stages of CKD, which were determined by a "Modification of Diet in Renal Disease" equation estimating the glomerular filtration rate (eGFR). The serum creatinine, eGFR and K+ levels were recorded at least twice during the study. We analyzed the average K+ level in these late-stage CKD patients.
RESULTS: The average K+ level increased along with renal function deterioration in the late stages of CKD (stage 3: 4.36 ± 0.49; stage 4: 4.50 ± 0.55; stage 5: 4.69 ± 0.73 mEq/L, p < 0.05). Men and patients with diabetes mellitus, a low eGFR, and a low hemoglobin might have higher levels of serum K+. We also noticed that there was a linear increase in the standard deviation of the serum K+ level as renal function deteriorated. The use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers was not associated with hyperkalemia in our patients.
CONCLUSION: Our results reflected that the serum K+ level increased in correlation with the decline in the eGFR in the late stages of CKD. Also, male gender, diabetes mellitus, and anemia might be risk factors for higher K+ levels in CKD patients. The variation in the serum K+ level became wider as renal failure progressed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880197

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  5 in total

1.  Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals.

Authors:  Elena Ramírez; Tomás Rossignoli; Armando J Campos; Raúl Muñoz; Claudia Zegarra; Hoi Tong; Nicolás Medrano; Alberto M Borobia; Antonio J Carcas; Jesús Frías
Journal:  Eur J Clin Pharmacol       Date:  2012-05-31       Impact factor: 2.953

2.  Comparative evaluation of essential and toxic elements in the blood of kidney failure patients and healthy referents.

Authors:  Abdul Haleem Panhwar; Tasneem Gul Kazi; Hassan Imran Afridi; Salma Aslam Arain; Mariam S Arain; Kapil Dev Brahman; Naeem Ullah; Jamshed Ali; Sadaf Sadia Arain
Journal:  Environ Monit Assess       Date:  2015-01-30       Impact factor: 2.513

3.  Evaluating the utility of rapid point-of-care potassium testing for the early identification of hyperkalemia in patients with chronic kidney disease in the emergency department.

Authors:  Je Sung You; Yoo Seok Park; Hyun Soo Chung; Hye Sun Lee; Youngseon Joo; Jong Woo Park; Sung Phil Chung; Shin Ho Lee; Hahn Shick Lee
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

4.  Serum phosphate as an additional marker for initiating hemodialysis in patients with advanced chronic kidney disease.

Authors:  Yueh-An Lu; Shen-Yang Lee; Hui-Yi Lin; Yen-Chun Liu; Huang-Kai Kao; Yung-Chang Chen; Ya-Chung Tian; Cheng-Chieh Hung; Chih-Wei Yang; Hsiang-Hao Hsu
Journal:  Biomed J       Date:  2016-01-19       Impact factor: 4.910

5.  Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan.

Authors:  Naoki Kashihara; Shun Kohsaka; Eiichiro Kanda; Suguru Okami; Toshitaka Yajima
Journal:  Kidney Int Rep       Date:  2019-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.